(Reuters) -GTCR has struck a 4.1 billion-euro ($4.80 billion) deal to buy Czech generic drug maker Zentiva from Advent International, the Financial Times reported on Wednesday, citing two people
Private equity GTCR strikes $4.8 billion deal to buy Zentiva, FT reports
GTCR's Acquisition of Zentiva
(Reuters) - Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drugmaker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unidentified sources.
Details of the Deal
Reuters could not immediately confirm the report. GTCR, Advent and Zentiva did not immediately respond to a Reuters request for comment.
Background on Zentiva
The deal has been finalized and is expected to be announced within days, the newspaper said.
Market Reactions
Boston-based Advent bought Zentiva, which makes a wide range of generic and over-the-counter drugs, from French pharmaceutical giant Sanofi for 1.9 billion euros in 2018.
Zentiva operates in over 30 countries and employs more than 5,000 people, according to the company's website.
India's Economic Times newspaper reported last month that Aurobindo Pharma was leading the race to buy Zentiva for up to $5.5 billion.
($1 = 0.8548 euros)
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sonia Cheema and Mrigank Dhaniwala)
